Cefepime,Tazobactam

Cefepime plus tazobactam is an injectable antibacterial combination consisting of cefepime, a fourth-generation cephalosporin, and tazobactam, a beta-lactamase inhibitor. Cefepime works by binding to bacterial penicillin-binding proteins and interfering with the synthesis of the bacterial cell wall, leading to bacterial death. Tazobactam inhibits certain beta-lactamase enzymes produced by bacteria and can protect cefepime from enzymatic degradation, thereby extending its activity against selected beta-lactamase-producing organisms. The combination is administered intravenously and has been investigated particularly for serious Gram-negative bacterial infections, including complicated urinary tract infections and acute pyelonephritis. Cefepime is primarily eliminated through the kidneys, making renal function an important consideration during treatment. Cefepime-tazobactam formulations have been developed in different ratios, including conventional 8:1 formulations used in India and the high-dose 1:1 combination known as WCK 4282. Because the regulatory status and clinical evidence differ between these formulations, the specific product and local prescribing information should be verified before use. The high-dose combination has been investigated as a potential carbapenem-sparing option against selected resistant Gram-negative bacteria.

Cefepime was developed as a fourth-generation cephalosporin with broad activity against many Gram-negative and Gram-positive bacteria, while tazobactam was developed as a beta-lactamase inhibitor to protect susceptible beta-lactam antibiotics from degradation by certain bacterial enzymes. Cefepime-tazobactam combinations have been marketed in India in different fixed ratios, including 8:1 formulations, while the high-dose 1:1 combination WCK 4282 was developed specifically using pharmacokinetic and pharmacodynamic principles to provide higher tazobactam exposure. WCK 4282 has undergone Phase I and Phase III clinical development, including studies evaluating renal impairment and treatment of complicated urinary tract infection or acute pyelonephritis. The European Union Clinical Trials Register records a Phase III study comparing cefepime-tazobactam with meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis. CDSCO records also show regulatory permission for a clinical trial of cefepime plus tazobactam in India in December 2023, using a 2 g cefepime plus 2 g tazobactam formulation for complicated urinary tract infection and acute pyelonephritis. The available regulatory records should not be interpreted as establishing a universal FDA or EMA marketing approval for cefepime-tazobactam as a combination.

Cefepime plus tazobactam is used or investigated for serious bacterial infections caused by susceptible organisms, particularly Gram-negative infections where beta-lactamase-mediated resistance may reduce the activity of cefepime alone. Clinical experience and published literature have described use of conventional cefepime-tazobactam formulations in infections such as hospital-acquired pneumonia, ventilator-associated pneumonia, urinary tract infections, bloodstream infections, and other serious bacterial infections, although evidence for older 8:1 formulations is more limited than for established comparator antibiotics. The high-dose 1:1 formulation WCK 4282 has specifically been developed and evaluated for complicated urinary tract infection and acute pyelonephritis and has been investigated as a potential treatment option for multidrug-resistant Gram-negative infections. Therapy should be guided by the suspected or confirmed pathogen, antimicrobial susceptibility results, infection site, severity of illness, local resistance patterns, and applicable regulatory information. Cefepime-tazobactam should not be assumed to be effective against organisms producing all types of carbapenemases or other resistance mechanisms.

Cefepime plus tazobactam is administered by intravenous infusion, with the exact dose and infusion duration depending on the formulation, indication, severity of infection, and renal function. Conventional products marketed in India commonly contain cefepime and tazobactam in an 8:1 ratio, including strengths such as 1 g/125 mg and 2 g/250 mg. The investigational high-dose WCK 4282 formulation uses a 1:1 ratio of 2 g cefepime plus 2 g tazobactam and has been studied as a 90-minute intravenous infusion every eight hours. Clinical pharmacokinetic studies demonstrated increasing cefepime and tazobactam exposure as renal function declined, supporting dose adjustment according to renal impairment. Treatment duration depends on the infection and clinical response and should follow the applicable product information and antimicrobial stewardship principles. Because different cefepime-tazobactam products contain substantially different amounts of tazobactam, doses from one formulation should not automatically be substituted for another.

Common adverse effects reported with cefepime-containing therapy and cefepime-tazobactam combinations include diarrhea, nausea, vomiting, rash, headache, injection-site reactions or phlebitis, and changes in liver enzymes or blood counts. Laboratory abnormalities such as positive direct Coombs testing or eosinophilia may also occur. Clinical studies of the high-dose cefepime-tazobactam combination have generally reported mostly mild-to-moderate adverse events, with liver enzyme elevations among the more frequently observed laboratory abnormalities. The likelihood and severity of adverse effects can vary according to the patient's age, renal function, underlying illness, duration of therapy, and other medicines being administered.

Important risks include serious hypersensitivity reactions, severe cutaneous reactions, antibiotic-associated diarrhea including Clostridioides difficile infection, and cefepime-associated neurotoxicity. Neurotoxicity can include confusion, encephalopathy, myoclonus, seizures, or non-convulsive status epilepticus and is particularly associated with excessive cefepime exposure in patients with renal impairment or when dosing is not appropriately adjusted. Serious allergic reactions are possible in patients with a history of severe beta-lactam hypersensitivity. Prolonged antibacterial treatment may also contribute to superinfection or selection of resistant organisms. Treatment should be interrupted or discontinued when clinically significant hypersensitivity, severe adverse reactions, or other serious toxicity occurs, according to the applicable prescribing information.

Renal function should be assessed before treatment and monitored during therapy because cefepime is predominantly eliminated through the kidneys and accumulation can increase the risk of neurotoxicity. Particular caution is required in elderly patients, patients with renal impairment, and patients receiving other medicines that may affect renal function or the central nervous system. A history of serious reactions to penicillins, cephalosporins, or other beta-lactam antibiotics should be reviewed before administration. Appropriate microbiological testing and antimicrobial susceptibility assessment should be used whenever feasible, especially when treating suspected multidrug-resistant infections. Cefepime and tazobactam do not have the extensive metabolic drug-interaction profile associated with many oral medicines, but concomitant nephrotoxic therapies and other medicines affecting renal function may require additional monitoring. As with other antibacterial agents, unnecessary prolonged use should be avoided to reduce the risk of antimicrobial resistance and secondary infections.

Prescribers and pharmacists should verify the exact cefepime-tazobactam formulation and ratio before dispensing or administration because conventional 8:1 products and the high-dose 1:1 WCK 4282 formulation are pharmacologically different dosing approaches. Baseline renal function should be documented and dosing should be adjusted according to the applicable product information. For serious infections, microbiological specimens should ideally be obtained before starting treatment when this does not delay necessary therapy, and treatment should subsequently be refined according to susceptibility results. Patients should be monitored for allergic reactions, gastrointestinal symptoms, neurological changes, injection-site complications, blood-count abnormalities, and liver-function changes where clinically appropriate. Particular attention should be given to new confusion, altered consciousness, myoclonus, or seizures in patients with renal impairment. Pharmacists should also check for duplication of beta-lactam antibiotics, renal-dose compatibility with concurrent medicines, and appropriate infusion preparation and administration requirements. Antibiotic selection should remain consistent with local antimicrobial stewardship policies and resistance patterns.